HIGHLIGHTS
- who: Wade T. Iams et al. from the Vanderbilt University Medical Center, Nashville, TN, USA have published the research: Journal Pre-proof, in the Journal: (JOURNAL) of May/28,/2021
SUMMARY
Oncogenic mutations in KRAS occur in approximately 26% and 11% of patients with lung adenocarcinoma in Western and Asian populations, respectively1-3. That changed on May 28, 2021, when the United_States Food and Drug Administration (FDA) granted accelerated approval to sotorasib for second-line or later treatment of patients with locally advanced or metastatic KRAS G12C mutant NSCLC. This was the first . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.